Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Hanmi Pharmaceuticals, Co. Ltd. - Product Pipeline Review - 2016', provides an overview of the Hanmi Pharmaceuticals, Co. Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Hanmi Pharmaceuticals, Co. Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Hanmi Pharmaceuticals, Co. Ltd. - The report provides overview of Hanmi Pharmaceuticals, Co. Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Hanmi Pharmaceuticals, Co. Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Hanmi Pharmaceuticals, Co. Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Hanmi Pharmaceuticals, Co. Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hanmi Pharmaceuticals, Co. Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hanmi Pharmaceuticals, Co. Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hanmi Pharmaceuticals, Co. Ltd. Snapshot 9 Hanmi Pharmaceuticals, Co. Ltd. Overview 9 Key Information 9 Key Facts 9 Hanmi Pharmaceuticals, Co. Ltd. - Research and Development Overview 10 Key Therapeutic Areas 10 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Combination Treatment Modalities 16 Pipeline Products - Partnered Products 17 Partnered Products/Combination Treatment Modalities 18 Pipeline Products - Out-Licensed Products 19 Out-Licensed Products/Combination Treatment Modalities 20 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products Glance 21 Hanmi Pharmaceuticals, Co. Ltd. - Late Stage Pipeline Products 21 Pre-Registration Products/Combination Treatment Modalities 21 Phase III Products/Combination Treatment Modalities 22 Hanmi Pharmaceuticals, Co. Ltd. - Clinical Stage Pipeline Products 23 Phase II Products/Combination Treatment Modalities 23 Phase I Products/Combination Treatment Modalities 24 Hanmi Pharmaceuticals, Co. Ltd. - Early Stage Pipeline Products 25 Preclinical Products/Combination Treatment Modalities 25 Discovery Products/Combination Treatment Modalities 26 Hanmi Pharmaceuticals, Co. Ltd. - Drug Profiles 27 HCP-1302 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 (HM30181A + paclitaxel) 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 eflapegrastim 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 HCP-1105 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 HCP-1303 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 HCP-1305 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 HCP-1401 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 HGP-0816 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 HGP-1207 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 HIP-1402 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ALG-1001 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 efpegsomatropin 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 olmutinib 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 poziotinib 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 KX-01 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 (HM30181A + irinotecan hydrochloride) 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 amlodipine besylate 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 HCP-1202 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 HCP-1405 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 HM-12525A 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 HM-71224 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 HM-95573 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 BH-03004 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Biologics for Diabetes 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Biologics for Obesity 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecules 1 for Autoimmune Disorders 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules 2 for Autoimmune Disorders 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules for Acute Myeloid Leukemia 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules for Fibrosis and Oncology 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Small Molecules for Oncology 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Biologics to Target CTLA4 and TNF Alpha 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Biologics to Target HER2 and CD3 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Biologics to Target HER2 and VEGFR 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 HM-12260B 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Small Molecules to Target ROR Gamma 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Analysis 65 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Target 65 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Route of Administration 67 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Molecule Type 68 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action 69 Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates 71 Hanmi Pharmaceuticals, Co. Ltd. - Dormant Projects 82 Hanmi Pharmaceuticals, Co. Ltd. - Locations And Subsidiaries 83 Head Office 83 Other Locations & Subsidiaries 83 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables
Hanmi Pharmaceuticals, Co. Ltd., Key Information 9 Hanmi Pharmaceuticals, Co. Ltd., Key Facts 9 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Indication, 2016 11 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Stage of Development, 2016 14 Hanmi Pharmaceuticals, Co. Ltd. - Monotherapy Products in Pipeline, 2016 15 Hanmi Pharmaceuticals, Co. Ltd. - Combination Treatment Modalities in Pipeline, 2016 16 Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products in Pipeline, 2016 17 Hanmi Pharmaceuticals, Co. Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 18 Hanmi Pharmaceuticals, Co. Ltd. - Out-Licensed Products in Pipeline, 2016 19 Hanmi Pharmaceuticals, Co. Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 20 Hanmi Pharmaceuticals, Co. Ltd. - Pre-Registration, 2016 21 Hanmi Pharmaceuticals, Co. Ltd. - Phase III, 2016 22 Hanmi Pharmaceuticals, Co. Ltd. - Phase II, 2016 23 Hanmi Pharmaceuticals, Co. Ltd. - Phase I, 2016 24 Hanmi Pharmaceuticals, Co. Ltd. - Preclinical, 2016 25 Hanmi Pharmaceuticals, Co. Ltd. - Discovery, 2016 26 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Target, 2016 65 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Route of Administration, 2016 67 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline by Molecule Type, 2016 68 Hanmi Pharmaceuticals, Co. Ltd. - Pipeline Products by Mechanism of Action, 2016 70 Hanmi Pharmaceuticals, Co. Ltd. - Recent Pipeline Updates, 2016 71 Hanmi Pharmaceuticals, Co. Ltd. - Dormant Developmental Projects,2016 82 Hanmi Pharmaceuticals, Co. Ltd., Other Locations 83 Hanmi Pharmaceuticals, Co. Ltd., Subsidiaries 83
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.